We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

94 hedge funds and large institutions have $167M invested in BioXcel Therapeutics in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 32 increasing their positions, 28 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more call options, than puts

Call options by funds: $2.11M | Put options by funds: $1.68M

14% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 28

0.09% less ownership

Funds ownership: 2.93% → 2.83% (-0.09%)

6% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 16

2% less funds holding

Funds holding: 96 → 94 (-2)

39% less capital invested

Capital invested by funds: $274M → $167M (-$106M)

Holders
94
Holders Change
-2
Holders Change %
-2.08%
% of All Funds
1.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
32
Reduced
28
Closed
16
Calls
$2.11M
Puts
$1.68M
Net Calls
+$432K
Net Calls Change
+$1.37M

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$2.22M
2
BlackRock
BlackRock
New York
+$1.87M
3
RCMNY
Rubric Capital Management (New York)
New York
+$1.62M
4
Voloridge Investment Management
Voloridge Investment Management
Florida
+$1.34M
5
Marshall Wace
Marshall Wace
United Kingdom
+$1.17M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$13.6M
2
Rafferty Asset Management
Rafferty Asset Management
New York
-$1.94M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.69M
4
Jane Street
Jane Street
New York
-$1.63M
5
GCM
Graham Capital Management
Connecticut
-$897K
Name Holding Trade Value Shares
Change 		Change in
Stake
Macquarie Group
76
Macquarie Group
Australia
$31K – – –
Citigroup
77
Citigroup
New York
$24K -$178K -845 -88%
UWM
78
Urban Wealth Management
California
$23K +$22.7K +108 New
MLICM
79
Metropolitan Life Insurance Company (MetLife)
New York
$17.2K – – –
AIP
80
Ameritas Investment Partners
Nebraska
$17K – – –
WTA
81
Washington Trust Advisors
Massachusetts
$16K +$13K +62 +388%
Fifth Third Bancorp
82
Fifth Third Bancorp
Ohio
$13K -$1.47K -7 -10%
Rockefeller Capital Management
83
Rockefeller Capital Management
New York
$11K -$14.5K -69 -55%
Canada Life
84
Canada Life
Manitoba, Canada
$10K – – –
National Bank of Canada
85
National Bank of Canada
Quebec, Canada
$10K – – –
Royal Bank of Canada
86
Royal Bank of Canada
Ontario, Canada
$9K -$5.26K -25 -37%
US Bancorp
87
US Bancorp
Minnesota
$8K -$1.47K -7 -16%
WAM
88
Worth Asset Management
Texas
$5K – – –
SWM
89
Spire Wealth Management
Virginia
$2K – – –
FDCDDQ
90
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.49K – – –
APC
91
Aspire Private Capital
North Carolina
$1K – – –
HFS
92
Hantz Financial Services
Michigan
$1K – – –
LWANC
93
Laurel Wealth Advisors (North Carolina)
North Carolina
$1K – – –
VVP
94
Venture Visionary Partners
Ohio
$528 +$631 +3 New
Rafferty Asset Management
95
Rafferty Asset Management
New York
– -$1.94M -5,808 Closed
Point72 Asset Management
96
Point72 Asset Management
Connecticut
– -$1.69M -5,056 Closed
Jane Street
97
Jane Street
New York
– -$1.63M -4,875 Closed
GCM
98
Graham Capital Management
Connecticut
– -$897K -2,682 Closed
ACA
99
Apis Capital Advisors
New York
– -$836K -2,500 Closed
ACM
100
ACT Capital Management
Pennsylvania
– -$418K -1,250 Closed
1 2 3
4
5

BTAI Hedge Fund Activity: Q2 2022 in Review

94 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q2 2022, worth a combined $167M — down 39% from $274M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of BTAI and 15 opened new positions — a net loss of 1 holder — while 28 trimmed existing stakes and 32 added.

The largest buyer was Millennium Management, adding an estimated $2.22M. The largest seller was State Street, cutting an estimated $13.6M.

  • 94 institutional investors held BioXcel Therapeutics (BTAI) as of Q2 2022, down from 96 in Q1 2022.
  • Funds reported $167M of BioXcel Therapeutics stock for Q2 2022, down 39% quarter-over-quarter.
  • 15 funds opened new BioXcel Therapeutics positions in Q2 2022 and 16 closed out, a net change of -1 holder.
  • The largest BioXcel Therapeutics buyer in Q2 2022 was Millennium Management, an estimated $2.22M added.
  • The largest BioXcel Therapeutics seller in Q2 2022 was State Street, an estimated $13.6M sold.

Based on aggregated 13F filings for Q2 2022.